Treatment of infections by OXA-48-producing Enterobacteriaceae

Antimicrobial Agents and Chemotherapy

Volumn 62, Issue 11, 2018, Pages

  Stewart, Adam ^a   Harris, Patrick ^a   Henderson, Andrew ^a   Paterson, David ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antibiotic resistance; Carbapenems; Enterobacteriaceae; Gram negative bacteria

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AVIBACTAM; AZTREONAM; BETA LACTAMASE INHIBITOR; CARBAPENEMASE; CARBAPENEMASE OXA 48; CEFEPIME; CEFTAZIDIME; COLISTIN; IMIPENEM; MEROPENEM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CARBAPENEMASE PRODUCING ENTEROBACTERIACEAE; CONTROLLED STUDY; ENTEROBACTERIACEAE INFECTION; ENZYME ACTIVITY; IN VITRO STUDY; KLEBSIELLA PNEUMONIAE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; ANIMAL; DRUG EFFECT; ENTEROBACTERIACEAE; HUMAN; METABOLISM; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 85055606300     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01195-18     Document Type: Article

References (74)

1. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. 2014. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis 20:1170–1175. https://doi.org/10.3201/eid2007.121004.
2. Mairi A, Pantel A, Sotto A, Lavigne JP, Touati A. 2017. OXA-48-like carbapenemases producing Enterobacteriaceae in different niches. Eur J Clin Microbiol Infect Dis 37:587–604. https://doi.org/10.1007/s10096-017-3112-7.
3. Lyman M, Walters M, Lonsway D, Rasheed K, Limbago B, Kallen A. 2015. Notes from the field: carbapenem-resistant Enterobacteriaceae producing OXA-48-like carbapenemases–United States, 2010–2015. MMWR Morb Mortal Wkly Rep 64:1315–1316. https://doi.org/10.15585/mmwr.mm6447a3.
4. Cuzon G, Ouanich J, Gondret R, Naas T, Nordmann P. 2011. Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 55:2420–2423. https://doi.org/10.1128/AAC.01452-10.
5. Poirel L, Potron A, Nordmann P. 2012. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 67:1597–1606. https://doi.org/10.1093/jac/dks121.
6. Bakthavatchalam YD, Anandan S, Veeraraghavan B. 2016. Laboratory detection and clinical implication of oxacillinase-48 like carbapenemase: the hidden threat. J Glob Infect Dis 8:41–50. https://doi.org/10.4103/0974-777X.176149.
7. Howard JC, Anderson T, Creighton J, Freeman JT. 13 July 2018. Geographical and temporal clustering of OXA-48-producing Escherichia coli ST410 causing community-onset urinary tract infection in Christchurch, New Zealand. J Antimicrob Chemother https://doi.org/10.1093/jac/dky269.
8. Loucif L, Chelaghma W, Helis Y, Sebaa F, Baoune RD, Zaatout W, Rolain JM. 2018. First detection of OXA-48-producing Klebsiella pneumoniae in community-acquired urinary tract infection in Algeria. J Glob Antimicrob Resist 12:115–116. https://doi.org/10.1016/j.jgar.2017.12.017.
9. Nordmann P, Poirel L. 2014. The difficult-to-control spread of carbapenemase producers among Enterobacteriaceae worldwide. Clin Microbiol Infect 20:821–830. https://doi.org/10.1111/1469-0691.12719.
10. Turton JF, Doumith M, Hopkins KL, Perry C, Meunier D, Woodford N. 2016. Clonal expansion of Escherichia coli ST38 carrying a chromosomally integrated OXA-48 carbapenemase gene. J Med Microbiol 65: 538–546. https://doi.org/10.1099/jmm.0.000248.
11. Evren E, Azap OK, Colakoglu S, Arslan H. 2013. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains. Diagn Microbiol Infect Dis 76:335–338. https://doi.org/10.1016/j.diagmicrobio.2013.04.004.
12. Poirel L, Heritier C, Nordmann P. 2004. Chromosome-encoded ambler class D beta-lactamase of Shewanella oneidensis as a progenitor of carbapenem-hydrolyzing oxacillinase. Antimicrob Agents Chemother 48: 348 –351. https://doi.org/10.1128/AAC.48.1.348-351.2004.
13. Poirel L, Heritier C, Tolun V, Nordmann P. 2004. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother 48:15–22. https://doi.org/10.1128/AAC.48.1.15-22.2004.
14. Carrër A, Poirel L, Eraksoy H, Cagatay AA, Badur S, Nordmann P. 2008. Spread of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in Istanbul, Turkey. Antimicrob Agents Chemother 52: 2950–2954. https://doi.org/10.1128/AAC.01672-07.
15. Humphries RM, Yang S, Hemarajata P, Ward KW, Hindler JA, Miller SA, Gregson A. 2015. First report of ceftazidime-avibactam resistance in a KPC-3-expressing Klebsiella pneumoniae isolate. Antimicrob Agents Chemother 59:6605– 6607. https://doi.org/10.1128/AAC.01165-15.
16. Potron A, Nordmann P, Lafeuille E, Al Maskari Z, Al Rashdi F, Poirel L. 2011. Characterization of OXA-181, a carbapenem-hydrolyzing class D beta-lactamase from Klebsiella pneumoniae. Antimicrob Agents Chemother 55:4896–4899. https://doi.org/10.1128/AAC.00481-11.
17. van Dijk K, Voets GM, Scharringa J, Voskuil S, Fluit AC, Rottier WC, Leverstein-Van Hall MA, Cohen Stuart JW. 2014. A disc diffusion assay for detection of class A, B and OXA-48 carbapenemases in Enterobacteriaceae using phenyl boronic acid, dipicolinic acid and temocillin. Clin Microbiol Infect 20:345–349. https://doi.org/10.1111/1469-0691.12322.
18. de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW. 2016. In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM Global Surveillance Study (2012 to 2014). Antimicrob Agents Chemother 60:3163–3169. https://doi.org/10.1128/AAC.03042-15.
19. Alatoom A, Elsayed H, Lawlor K, AbdelWareth L, El-Lababidi R, Cardona L, Mooty M, Bonilla MF, Nusair A, Mirza I. 2017. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Int J Infect Dis 62: 39–43. https://doi.org/10.1016/j.ijid.2017.06.007.
20. Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2014. Efficacy of humanized carbapenem and ceftazidime regimens against Enterobacteriaceae producing OXA-48 carbapenemase in a murine infection model. Antimicrob Agents Chemother 58:1678 –1683. https://doi.org/10.1128/AAC.01947-13.
21. Aktas Z, Kayacan C, Oncul O. 2012. In vitro activity of avibactam (NXL104) in combination with beta-lactams against Gram-negative bacteria, including OXA-48 beta-lactamase-producing Klebsiella pneumoniae. Int J Antimicrob Agents 39:86 – 89. https://doi.org/10.1016/j.ijantimicag.2011.09.012.
22. Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N. 2017. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 72:1373–1385. https://doi.org/10.1093/jac/dkw593.
23. Haidar G, Clancy CJ, Chen L, Samanta P, Shields RK, Kreiswirth BN, Nguyen MH. 2017. Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00642-17. https://doi.org/10.1128/AAC.00642-17.
24. Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M. 2018. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 62:e01856-17. https://doi.org/10.1128/AAC.01856-17.
25. Krishnappa LG, Marie MA, Al Sheikh YA. 2015. Characterization of carbapenem resistance mechanisms in Klebsiella pneumoniae and in vitro synergy of the colistin-meropenem combination. J Chemother 27: 277–282. https://doi.org/10.1179/1973947814Y.0000000197.
26. Lutgring JD, Zhu W, de Man TJB, Avillan JJ, Anderson KF, Lonsway DR, Rowe LA, Batra D, Rasheed JK, Limbago BM. 2018. Phenotypic and genotypic characterization of enterobacteriaceae producing oxacillinase-48-like carbapenemases, United States. Emerg Infect Dis 24:700 –709. https://doi.org/10.3201/eid2404.171377.
27. Navarro-San Francisco C, Mora-Rillo M, Romero-Gomez MP, Moreno-Ramos F, Rico-Nieto A, Ruiz-Carrascoso G, Gomez-Gil R, Arribas-Lopez JR, Mingorance J, Pano-Pardo JR. 2013. Bacteraemia due to OXA-48carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin Microbiol Infect 19:E72–E79. https://doi.org/10.1111/1469-0691.12091.
28. Balkan II, Aygun G, Aydin S, Mutcali SI, Kara Z, Kuskucu M, Midilli K, Semen V, Aras S, Yemisen M, Mete B, Ozaras R, Saltoglu N, Tabak F, Ozturk R. 2014. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival. Int J Infect Dis 26:51–56. https://doi.org/10.1016/j.ijid.2014.05.012.
29. Ahn C, Butt AA, Rivera JI, Yaqoob M, Hag S, Khalil A, Pitout M, Doi Y. 2015. OXA-48-producing Enterobacteriaceae causing bacteremia, United Arab Emirates. Int J Infect Dis 30:36 –37. https://doi.org/10.1016/j.ijid.2014.11.008.
30. Poirel L, Kieffer N, Nordmann P. 2016. In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 71:156 –161. https://doi.org/10.1093/jac/dkv294.
31. Galani I, Nafplioti K, Chatzikonstantinou M, Souli M. 21 March 2018. In vitro evaluation of double-carbapenem combinations against OXA-48producing Klebsiella pneumoniae isolates using time-kill studies. J Med Microbiol https://doi.org/10.1099/jmm.0.000725.
32. Woodford N, Pike R, Meunier D, Loy R, Hill R, Hopkins KL. 2014. In vitro activity of temocillin against multidrug-resistant clinical isolates of Escherichia coli, Klebsiella spp. and Enterobacter spp., and evaluation of high-level temocillin resistance as a diagnostic marker for OXA-48 carbapenemase. J Antimicrob Chemother 69:564–567. https://doi.org/10.1093/jac/dkt383.
33. Vasoo S, Cunningham SA, Cole NC, Kohner PC, Menon SR, Krause KM, Harris KA, De PP, Koh TH, Patel R. 2015. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing Gram-negative bacilli. Antimicrob Agents Chemother 59:7842–7846. https://doi.org/10.1128/AAC.02019-15.
34. Jayol A, Poirel L, Dortet L, Nordmann P. 2016. National survey of colistin resistance among carbapenemase-producing Enterobacteriaceae and outbreak caused by colistin-resistant OXA-48-producing Klebsiella pneumoniae, France, 2014. Euro Surveill 21:pii30339. https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2016.21.37.30339.
35. Oteo J, Ortega A, Bartolome R, Bou G, Conejo C, Fernandez-Martinez M, Gonzalez-Lopez JJ, Martinez-Garcia L, Martinez-Martinez L, Merino M, Miro E, Mora M, Navarro F, Oliver A, Pascual A, Rodriguez-Bano J, Ruiz-Carrascoso G, Ruiz-Garbajosa P, Zamorano L, Bautista V, Perez-Vazquez M, Campos J, Geih G, Reipi. 2015. Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem. Antimicrob Agents Chemother 59:3406–3412. https://doi.org/10.1128/AAC.00086-15.
36. Samuelsen O, Overballe-Petersen S, Bjornholt JV, Brisse S, Doumith M, Woodford N, Hopkins KL, Aasnaes B, Haldorsen B, Sundsfjord A, Norwegian Study Group on, CPE. 2017. Molecular and epidemiological characterization of carbapenemase-producing Enterobacteriaceae in Norway, 2007 to 2014. PLoS One 12:e0187832. https://doi.org/10.1371/journal.pone.0187832.
37. García-Castillo M, Garcia-Fernandez S, Gomez-Gil R, Pitart C, Oviano M, Gracia-Ahufinger I, Diaz-Reganon J, Tato M, Canton R, iCREST Study Group. 2018. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain. Int J Antimicrob Agents 51:511–515. https://doi.org/10.1016/j.ijantimicag.2018.01.011.
38. Ozbek B, Mataraci-Kara E, Er S, Ozdamar M, Yilmaz M. 2015. In vitro activities of colistin, tigecycline and tobramycin, alone or in combination, against carbapenem-resistant Enterobacteriaceae strains. J Glob Antimicrob Resist 3:278–282. https://doi.org/10.1016/j.jgar.2015.09.001.
39. Castanheira M, Huband MD, Mendes RE, Flamm RK. 2017. Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother 61:e00567-17. https://doi.org/10.1128/AAC.00567-17.
40. VanScoy BD, Trang M, McCauley J, Conde H, Bhavnani SM, Friedrich LV, Alexander DC, Ambrose PG. 2016. Pharmacokinetics-pharmacodynamics of a novel beta-lactamase inhibitor, CB-618, in combination with meropenem in an in vitro infection model. Antimicrob Agents Chemother 60:3891–3896. https://doi.org/10.1128/AAC.02943-15.
41. Shapiro AB. 2017. Kinetics of sulbactam hydrolysis by beta-lactamases, and kinetics of beta-lactamase inhibition by sulbactam. Antimicrob Agents Chemother 61:e01612-17. https://doi.org/10.1128/AAC.01612-17.
42. Durand-Réville TF, Guler S, Comita-Prevoir J, Chen B, Bifulco N, Huynh H, Lahiri S, Shapiro AB, McLeod SM, Carter NM, Moussa SH, Velez-Vega C, Olivier NB, McLaughlin R, Gao N, Thresher J, Palmer T, Andrews B, Giacobbe RA, Newman JV, Ehmann DE, de Jonge B, O’Donnell J, Mueller JP, Tommasi RA, Miller AA. 2017. ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2:17104. https://doi.org/10.1038/nmicrobiol.2017.104.
43. Mushtaq S, Vickers A, Woodford N, Livermore DM. 2017. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D beta-lactamases. J Antimicrob Chemother 72:1688–1695. https://doi.org/10.1093/jac/dkx035.
44. Vallejo JA, Martinez-Guitian M, Vazquez-Ucha JC, Gonzalez-Bello C, Poza M, Buynak JD, Bethel CR, Bonomo RA, Bou G, Beceiro A. 2016. LN-1-255, a penicillanic acid sulfone able to inhibit the class D carbapenemase OXA-48. J Antimicrob Chemother 71:2171–2180. https://doi.org/10.1093/jac/dkw105.
45. Akhter S, Lund BA, Ismael A, Langer M, Isaksson J, Christopeit T, Leiros HS, Bayer A. 2018. A focused fragment library targeting the antibiotic resistance enzyme - oxacillinase-48: synthesis, structural evaluation and inhibitor design. Eur J Med Chem 145:634 – 648. https://doi.org/10.1016/j.ejmech.2017.12.085.
46. Livermore DM, Mushtaq S, Warner M, Turner SJ, Woodford N. 2018. Potential of high-dose cefepime/tazobactam against multiresistant Gram-negative pathogens. J Antimicrob Chemother 73:126 –133. https://doi.org/10.1093/jac/dkx360.
47. Livermore DM, Mushtaq S, Meunier D, Hopkins KL, Hill R, Adkin R, Chaudhry A, Pike R, Staves P, Woodford N, Committee BRSS. 2017. Activity of ceftolozane/tazobactam against surveillance and “problem” Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles. J Antimicrob Chemother 72:2278–2289. https://doi.org/10.1093/jac/dkx136.
48. Rodríguez-Avial I, Pena I, Picazo JJ, Rodriguez-Avial C, Culebras E. 2015. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Int J Antimicrob Agents 46:616 – 621. https://doi.org/10.1016/j.ijantimicag.2015.07.021.
49. Galani I, Anagnostoulis G, Chatzikonstantinou M, Petrikkos G, Souli M. 2016. Emergence of Klebsiella pneumoniae co-producing OXA-48, CTX-M-15, and ArmA in Greece. Clin Microbiol Infect 22:898–899. https://doi.org/10.1016/j.cmi.2016.08.002.
50. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M, Yamano Y. 2016. In vitro antimicrobial activity of a siderophore cephalosporin, S-649266, against Enterobacteriaceae clinical isolates, including carbapenem-resistant strains. Antimicrob Agents Chemother 60:729 –734. https://doi.org/10.1128/AAC.01695-15.
51. Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. 2018. In vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 51:62– 64. https://doi.org/10.1016/j.ijantimicag.2017.06.022.
52. Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. 2017. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014–2015. Diagn Microbiol Infect Dis 91:51–62. https://doi.org/10.1016/j.diagmicrobio.2017.12.013.
53. Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. 2013. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother 57:5548–5558. https://doi.org/10.1128/AAC.01288-13.
54. Maseda E, Salgado P, Anillo V, Ruiz-Carrascoso G, Gomez-Gil R, Martin-Funke C, Gimenez MJ, Granizo JJ, Aguilar L, Gilsanz F. 2017. Risk factors for colonization by carbapenemase-producing enterobacteria at admission to a surgical ICU: a retrospective study. Enferm Infecc Microbiol Clin 35:333–337. https://doi.org/10.1016/j.eimc.2016.02.017.
55. Dautzenberg MJ, Ossewaarde JM, de Greeff SC, Troelstra A, Bonten MJ. 2016. Risk factors for the acquisition of OXA-48-producing Enterobacteriaceae in a hospital outbreak setting: a matched case-control study. J Antimicrob Chemother 71:2273–2279. https://doi.org/10.1093/jac/dkw119.
56. Madueño A, Gonzalez Garcia J, Aguirre-Jaime A, Lecuona M. 2017. A hospital-based matched case-control study to identify risk factors for clinical infection with OXA-48-producing Klebsiella pneumoniae in rectal carriers. Epidemiol Infect 145:2626–2630. https://doi.org/10.1017/S095026881700142X.
57. Semin-Pelletier B, Cazet L, Bourigault C, Juvin ME, Boutoille D, Raffi F, Hourmant M, Blancho G, Agard C, Connault J, Corvec S, Caillon J, Batard E, Lepelletier D. 2015. Challenges of controlling a large outbreak of OXA-48 carbapenemase-producing Klebsiella pneumoniae in a French university hospital. J Hosp Infect 89:248–253. https://doi.org/10.1016/j.jhin.2014.11.018.
58. Goren MG, Chmelnitsky I, Carmeli Y, Navon-Venezia S. 2011. Plasmid-encoded OXA-48 carbapenemase in Escherichia coli from Israel. J Antimicrob Chemother 66:672–673. https://doi.org/10.1093/jac/dkq467.
59. Levast M, Poirel L, Carrer A, Deiber M, Decroisette E, Mallaval FO, Lecomte C, Nordmann P. 2011. Transfer of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae from Turkey to France. J Antimicrob Chemother 66:944–945. https://doi.org/10.1093/jac/dkq504.
60. Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jimenez-Martin MJ, Martinez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos Ramos JC, Rodriguez M, Sanchez-Garcia M, Viale P, Wolff M, Carmeli Y. 2017. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 61:e01964-16. https://doi.org/10.1128/AAC.01964-16.
61. Castón JJ, Lacort-Peralta I, Martin-Davila P, Loeches B, Tabares S, Temkin L, Torre-Cisneros J, Pano-Pardo JR. 2017. Clinical efficacy of ceftazidime/ avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis 59:118–123. https://doi.org/10.1016/j.ijid.2017.03.021.
62. Livermore DM, Meunier D, Hopkins KL, Doumith M, Hill R, Pike R, Staves P, Woodford N. 8 December 2017. Activity of ceftazidime/ avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015–16. J Antimicrob Chemother https://doi.org/10.1093/jac/dkx438.
63. Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. 2014. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58:654–663. https://doi.org/10.1128/AAC.01222-13.
64. Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh PR, Viale P, Pano-Pardo JR, Venditti M, Tumbarello M, Daikos G, Canton R, Doi Y, Tuon FF, Karaiskos I, Perez-Nadales E, Schwaber MJ, Azap OK, Souli M, Roilides E, Pournaras S, Akova M, Perez F, Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodriguez-Bano J, REIPI/ESGBIS/INCREMENT Investigators. 2017. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 17: 726–734. https://doi.org/10.1016/S1473-3099(17)30228-1.
65. Ouertani R, Limelette A, Guillard T, Brasme L, Jridi Y, Barguellil F, El Salabi A, de Champs C, Chouchani C. 2016. First report of nosocomial infection caused by Klebsiella pneumoniae ST147 producing OXA-48 and VEB-8 beta-lactamases in Tunisia. J Glob Antimicrob Resist 4:53–56. https://doi.org/10.1016/j.jgar.2015.10.002.
66. Hajjej Z, Gharsallah H, Naija H, Boutiba I, Labbene I, Ferjani M. 2016. Successful treatment of a carbapenem-resistant Klebsiella pneumoniae carrying bla OXA-48, bla VIM-2, bla CMY-2 and bla SHV- with high dose combination of imipenem and amikacin. IDCases 4:10–12. https://doi.org/10.1016/j.idcr.2016.01.003.
67. Balkan II, Batirel A, Karabay O, Agalar C, Akalin S, Alici O, Alp E, Altay FA, Altin N, Arslan F, Aslan T, Bekiroglu N, Cesur S, Celik AD, Dogan M, Durdu B, Duygu F, Engin A, Engin DO, Gonen I, Guclu E, Guven T, Hatipoglu CA, Hosoglu S, Karahocagil MK, Kilic AU, Ormen B, Ozdemir D, Ozer S, Oztoprak N, Sezak N, Turhan V, Turker N, Yilmaz H. 2015. Comparison of colistin monotherapy and non-colistin combinations in the treatment of multi-drug resistant Acinetobacter spp. bloodstream infections: a multicenter retrospective analysis. Indian J Pharmacol 47:95–100. https://doi.org/10.4103/0253-7613.150383.
68. Jayol A, Nordmann P, Poirel L, Dubois V. 2018. Ceftazidime/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 73:542–544. https://doi.org/10.1093/jac/dkx393.
69. Goerger E, Honnorat E, Savini H, Coulange M, Bergmann E, Simon F, Seng P, Stein A. 2016. Anti-infective therapy without antimicrobials: apparent successful treatment of multidrug resistant osteomyelitis with hyperbaric oxygen therapy. IDCases 6:60–64. https://doi.org/10.1016/j.idcr.2016.09.008.
70. Karlowsky JA, Kazmierczak KM, Bouchillon SK, de Jonge BLM, Stone GG, Sahm DF. 2018. In vitro activity of ceftazidime-avibactam against clinical isolates of Enterobacteriaceae and Pseudomonas aeruginosa collected in Asia-Pacific countries: results from the INFORM Global Surveillance Program, 2012 to 2015. Antimicrob Agents Chemother 62:e02569-17. https://doi.org/10.1128/AAC.02569-17.
71. Pfaller MA, Huband MD, Mendes RE, Flamm RK, Castanheira M. 2018. In vitro activity of meropenem-vaborbactam and characterization of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem-vaborbactam surveillance program. Int J Antimicrob Agents 52:144–150. https://doi.org/10.1016/j.ijantimicag.2018.02.021.
72. Karlowsky JA, Lob SH, Kazmierczak KM, Badal RE, Young K, Motyl MR, Sahm DF. 2017. In vitro activity of imipenem against carbapenemase-positive Enterobacteriaceae isolates collected by the SMART Global Surveillance Program from 2008 to 2014. J Clin Microbiol 55:1638–1649. https://doi.org/10.1128/JCM.02316-16.
73. Livermore DM, Mushtaq S, Warner M, Zhang JC, Maharjan S, Doumith M, Woodford N. 2011. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J Antimicrob Chemother 66:48–53. https://doi.org/10.1093/jac/dkq408.
74. Martins AF, Bail L, Ito CAS, da Silva Nogueira K, Dalmolin TV, Martins AS, Rocha JLL, Serio AW, Tuon FF. 2018. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers. Diagn Microbiol Infect Dis 90:228–232. https://doi.org/10.1016/j.diagmicrobio.2017.11.004.